» Articles » PMID: 39821819

Dietary Flaxseed: Cardiometabolic Benefits and Its Role in Promoting Healthy Aging

Overview
Journal Geroscience
Date 2025 Jan 17
PMID 39821819
Authors
Affiliations
Soon will be listed here.
Abstract

Flaxseed, a rich source of omega-3 polyunsaturated fatty acid alpha-linolenic acid (ALA), lignans, and soluble fiber, has attracted attention for its potential to improve multiple cardiometabolic risk factors. While its benefits are well-recognized, comprehensive evaluations of its direct impact on clinical outcomes, such as the prevention or progression of cardiometabolic diseases, remain limited. Additionally, its potential to support healthy aging and longevity through fundamental biological mechanisms has not been fully elucidated. This review synthesizes existing research on flaxseed supplementation, highlighting its effects on cardiometabolic risk factors and outcomes, the underlying biological mechanisms, and its broader implications for health promotion and aging. Findings demonstrate that flaxseed supplementation significantly improves several cardiometabolic risk factors, including body weight, body mass index, lipid levels, blood pressure, glycemic measures, markers of inflammation (e.g., C-reactive protein and interleukin-6), oxidative stress, and liver enzymes. Blood pressure reductions range from approximately 2 to 15 mmHg for systolic blood pressure and 1 to 7 mmHg for diastolic blood pressure, with the magnitude influenced by dose, duration, and baseline risk profiles. While direct evidence linking flaxseed to the prevention of hypertension, metabolic syndrome, metabolic dysfunction-associated steatotic liver disease, type 2 diabetes, chronic kidney disease, and cardiovascular disease is limited, its bioactive components-ALA, lignans, and fiber-are strongly associated with reduced risks of these conditions. The benefits of flaxseed are mediated through multiple pathways, including anti-inflammatory and antioxidant effects, improved lipid levels, improved glucose metabolism and insulin sensitivity, modulation of gut microbiota, and enhanced vascular health. Beyond cardiometabolic outcomes, flaxseed may influence key biological processes relevant to aging, underscoring its potential to promote healthy aging and longevity. Optimal cardiometabolic benefits appear to be achieved with ground whole flaxseed at doses of ≥ 30 g/day for at least 12 weeks, particularly among individuals at high cardiometabolic risk. Future research should focus on elucidating flaxseed's mechanisms of action, clarifying its role in disease prevention, and refining dietary recommendations to harness its potential for cardiometabolic health and aging interventions.

Citing Articles

Flaxseed Improves Glucose and Lipid Metabolism in Mexican Subjects with Type 2 Diabetes: A Parallel Randomized Clinical Trial.

Lopez-Toledo S, Pineda De la Cruz M, Gutierrez-Hurtado I, Gijon-Soriano A, Martinez-Martinez E, Valencia-Santiago C Nutrients. 2025; 17(4).

PMID: 40005038 PMC: 11858396. DOI: 10.3390/nu17040709.

References
1.
Mills K, Stefanescu A, He J . The global epidemiology of hypertension. Nat Rev Nephrol. 2020; 16(4):223-237. PMC: 7998524. DOI: 10.1038/s41581-019-0244-2. View

2.
Sattar N, Gaw A, Scherbakova O, Ford I, OReilly D, Haffner S . Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003; 108(4):414-9. DOI: 10.1161/01.CIR.0000080897.52664.94. View

3.
Laaksonen D, Lakka H, Niskanen L, Kaplan G, Salonen J, Lakka T . Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002; 156(11):1070-7. DOI: 10.1093/aje/kwf145. View

4.
Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M . Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001; 24(4):683-9. DOI: 10.2337/diacare.24.4.683. View

5.
Lakka H, Laaksonen D, Lakka T, Niskanen L, Kumpusalo E, Tuomilehto J . The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002; 288(21):2709-16. DOI: 10.1001/jama.288.21.2709. View